US Election 2016
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
With an all-Republican House, Senate and administration lined up to lead the government following the 2016 elections, the path is clear for passage of a set of FDA reforms to ease device approvals embedded in a combined House 'Cures' and Senate medical innovation package. It could even happen over the upcoming lame-duck session, before the new administration and Congress take over. But controversy around price-gouging by drug firms still could stymie quick Cures bill passage, an industry attorney predicts. Meanwhile, medtech industry groups plan to seize on the Trump victory as a means to achieve permanent device tax repeal.
Latest From Elections & Medical Device
Congressional investigations are harrowing events, if rare, for even the most organized device manufacturer. Speakers at a recent conference discussed how they happen and what strategies may help you get through them.
As the top medtech lobby groups continue to push for a permanent repeal of the medical device excise tax, one of their top lobbyists and medtech executives says it’s far more likely they will see another multiyear moratorium considering the political reality.
Sen. Johnny Isakson, R-GA, who has sponsored and backed several key pieces of device-industry legislation over the last several years, said on 28 August that he will retire from the US Senate on 31 December 2019, due to health challenges.
In an address to the National Press Club on 10 May, former FDA Commissioner Scott Gottlieb pointed to some of the challenges that CMS would face in supplying coverage for new technology, should a "Medicare for All" bill be adopted by Congress and signed by the president. Medtech Insight analyzed provisions that could impact industry in some of the proposed bills, in a comparative chart.
Stryker CEO Kevin Lobo says while repeal of the medical device tax is his top issue, there are four main priorities he wants to work on over the next two years as industry advocate group AdvaMed’s board chair. They include better public engagement, increased advocacy work with the new Congress, advancing new technology – especially start-ups – and increasing diversity in the medtech industry.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.